Piper Sandler initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $75 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines initiated with an Outperform at LifeSci Capital
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Overweight at Wells Fargo
- Revolution Medicines’ Innovative RAS(ON) Platform and Strategic Collaborations Drive Buy Rating
- Revolution Medicines’ Earnings Call: Progress Amid Challenges